CSL has invested $117 million upfront in Dutch biotech VarmX, obtaining an option to acquire its Phase 3-ready drug candidate poised to reverse anticoagulant effects, such as those from Eliquis, potentially addressing risks of internal bleeding. The deal supports accelerating clinical development and positions CSL to expand its product portfolio in blood coagulation management.